22 April 2021 
EMA/CHMP/230979/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Tagrisso 
osimertinib 
On 22 April 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Tagrisso. The marketing authorisation holder for this medicinal product is AstraZeneca AB. 
The CHMP adopted a new indication as follows: 
TAGRISSO as monotherapy is indicated for the adjuvant treatment after complete tumour 
resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours 
have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution 
mutations (see section 5.1). 
For information, the full indications for Tagrisso will be as follows2: 
Tagrisso as monotherapy is indicated for: 
the adjuvant treatment after complete tumour resection in adult patients with 
• 
stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal 
growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution 
mutations (see section 5.1). 
the first-line treatment of adult patients with locally advanced or metastatic NSCLC with 
• 
activating EGFR mutations. 
• 
mutation-positive NSCLC. 
the treatment of adult patients with locally advanced or metastatic EGFR T790M 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
